



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Applicants: Hiroyuki ABURATANI, et al.

Application No.: 10/526,741

Filing Date: November 14, 2005

For: **ANTIBODY AGAINST SECRETED N-TERMINAL PEPTIDE OF GPC3 PRESENT IN BLOOD OR C-TERMINAL PEPTIDE OF GPC3**

Examiner: Peter J. Reddig

Art Unit: 1642

Confirmation No.: 4248

MAIL STOP: AF  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

July 9, 2007

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby submit this Supplemental Information Disclosure Statement, including one (1) sheet of Form PTO-1449, for consideration by the Examiner in connection with the above-identified patent application. The references listed on the enclosed Form PTO-1449 were cited in the Partial European Search Report issued in connection with corresponding European Patent Application No. 07005887.0 "not more than three month prior to the filing of the information disclosure statement." A copy of the Search Report is enclosed as Appendix A.

In accordance with provisions of 37 C.F.R. § 1.98 (a)(2), copies of the listed references are enclosed. If a copy of any of the listed references is missing, it is respectfully requested that the Examiner contacts the undersigned attorney for the Applicants, so that the missing copy can be provided.

07/11/2007 RFEKADU1 00000049 10526741

01 FC:1606 180.00 0P

Applicants respectfully note that the following reference listed in the Search Report, but not on the enclosed PTO-1449, was previously brought to the attention of the Examiner in the Information Disclosure Statement filed June 13, 2006: Lage et al.: "Expression of a glypican-related 62-kDa antigen is decreased in hepatocellular carcinoma in correspondence to the grade of tumor differentiation," *Virchows Archiv*, vol. 438, no. 6, June 2001, pages 568-573.


Applicants further note that the following references listed in the Search Report, but not on the enclosed Form PTO-1449, were previously brought to the attention of the Examiner in the Information Disclosure Statement filed November 10, 2005:

- 1) WO 03/010336 to Debuschewitz et al.;
- 2) M.I. CAPPURO, et al., "Overexpression of Glypican-3 in Human Hepatocellular Carcinomas Determined by Immunohistochemistry Using a Monoclonal Antibody," *Proceedings of the American Association for Cancer Research Annual Meeting*, March 2002, Vol. 43, pg. 219;
- 3) Y. MIDORIKAWA, et al., Glypican-3, "Overexpressed in Hepatocellular Carcinoma, Modulates FGF2 and BMP-& Signaling," *International Journal of Cancer*, February 10, 2003, Vol. 103, No. 4, pp. 455-465;
- 4) Y.K. SUNG, et al., "Glypican-3 is Overexpressed in Human Hepatocellular Carcinoma," *Cancer Science*, March 2003, Vol. 94, No. 3, pp. 259-262; and
- 5) M. CAPURRO, et al., "Glypican-3: A Novel Serum and Histochemical Marker for Hepatocellular Carcinoma," *Gastroenterology*, July 2003, Vol. 125(1), pp. 89-97.

In accordance with provisions of 37 C.F.R. § 1.97(e), Applicants state that "each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the information disclosure statement," namely a Partial European Search Report dated June 12, 2007, issued from the European Patent Office in connection with European Patent Application No. 03794236.4.

This information disclosure statement is being submitted under 37 C.F.R. § 1.97(d), accordingly a check for \$180.00 to cover the fee believed due is enclosed. If any additional fees are due or an overpayment has been made, the Commissioner is authorized to charge such fees or credit such overpayment to Deposit Account No. 50-0552.

Respectfully submitted,  
DAVIDSON, DAVIDSON & KAPPEL, LLC

By:   
Cary S. Kappel  
Reg. No. 36,561

Davidson, Davidson & Kappel, LLC  
485 Seventh Avenue, 14<sup>th</sup> Floor  
New York, New York 10018  
(212) 736-1940

FORM PTO-1449 (REV. 7-86)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 392.1002		SERIAL NO.: 10/526,741	
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)				APPLICANT(S): Aburatani et al.			
				FILING DATE: November 14, 2005		GROUP: 1642	

U.S. PATENT DOCUMENTS													
*EXAMINER INITIAL	AA	AB	AC	AD	AE	AF	AG	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS														
									DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
AM	"Datasheet from antibody glypican-3 (W-18): sc10455" [Online], 12 January 2001 (2001-01-12), XP002434152; Santa Cruz Biotechnology Homepage Retrieved from the Internet: URL: <a href="http://datasheets.scbt.com/sc-10455.pdf">http://datasheets.scbt.com/sc-10455.pdf</a>
AN	"Datasheet from antibody glypican-3 (H-162): sc11395" [Online] 24 August 2001 (2001-08-24), XP 002434126; Retrieved from the Internet: URL: <a href="http://datasheets.scbt.com/sc-10395.pdf">http://datasheets.scbt.com/sc-10395.pdf</a>
AO	
AP	
AQ	
AR	
AS	

EXAMINER	DATE CONSIDERED
----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.